Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and ...

The Biosimilars Market is valued at USD 34.61 Billion in 2024 and is expected to reach USD 205.65 Billion by 2035 at a CAGR of 17.60% over the forecast period 2025-2035. The Biosimilars Market ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Pharmacy benefit managers take different approaches to controlling ...

Biosimilar market shares have risen, notably in oncology, ophthalmology, and pegfilgrastim, with significant FDA approvals enhancing competition. Adalimumab biosimilars struggle due to pharmacy ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and Neulasta. Humira now faces competition from seven biosimilars, while Neulasta has ...

As policy makers try to address unsustainable prices for biologic drugs, concerns about the fledgling US market for biosimilars have come to the forefront. Some experts have even suggested abandoning ...

Biosimilar medication, generic versions of typically expensive biologic-based drugs, are set to save patients and the health care system $180B over the next five years as even more hit the market. New ...

Fact: branded biologic drugs are consistently among the most expensive in our healthcare system. 1 Compounding this, chronic conditions – often treated with biologics – are becoming increasingly ...